VJOncology had the opportunity to conduct in-person interviews with these experts and obtain their perspectives on the latest progress within the field.
See our top editorial picks below, and more at VJOncology.com.
Alexander Spira KRYSTAL-1: adagrasib in patients with KRASG12Cm NSCLC Alexander Spira reports on the results of Cohort A of the KRYSTAL-1 trial evaluating adagrasib in patients with NSCLC previously treated with platinum-based chemotherapy and anti-PD-1/L1 therapy.
Marla Lipsyc-Sharf ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer Of the 83 evaluable patients in a study evaluating ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer, 10% had detectable ctDNA more than 5 years after initial diagnosis.
Joaquim Bellmunt JAVELIN Bladder 100: avelumab maintenance for bladder cancer The JAVELIN Bladder 100 study investigated avelumab maintenance therapy for patients with metastatic or locally advanced bladder cancer.
Takayuki Yoshino Panitumumab + mFOLOFOX6 as the new SOC for RAS WT mCRC The study compared the anti-EGFR panitumumab versus the anti-VEGFR bevacizumab with mFOLFOX6 as first-line treatment
Eva Segelov SerOzNET study: SARS-CoV-2 post-vaccine surveillance study in Australian patients with cancer Dr Segelov aims to improve understanding of the safety and efficacy of the COVID-19 vaccines in patients with specific cancers.
John Strickler CodeBreak100: sotorasib in patients with KRASG12Cm pancreatic cancer CodeBreak100 explores the KRAS p.G12C inhibitor, sotorasib, in patients with previously treated pancreatic cancer harboring the KRAS p.G12C mutation.
🎧Take a listen to our latest VJOncology podacsts providing you daily round-ups live from ASCO 2022!
Check out our disease channels!
Check out more developments across different disease types with our dedicated disease channels, featuring expert interviews, podcasts, roundtable discussions and more
